REZOLUTE, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
REZOLUTE, INC. (RZLT) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $334.23 thousand as of 2018-12-31, per its 10-Q filed 2019-02-14.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2019-09-10
- 2018-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $334.23K.
- 2018-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.21M.
- 2018-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.92M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2018-12-31 | $334.23K 10-Q · filed 2019-02-14 |
| 2018-09-30 | $1.21M 10-Q · filed 2018-12-14 |
| 2018-06-30 | $1.92M 10-K · filed 2019-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |